212P A phase Ib/II study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer

V.F. Borges, J. Chien, S. Nunnery, J.A. Mouabbi, C.X. Ma, S. Bahadur, J. Chaves, D.A. Potter,D. Sabanathan,A.R. Tan, L. Sun,D. Faltaos, M. Tonda,N.U. Lin

ESMO Open（2024）

引用 0|浏览7

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要